Man Group plc Boosts Position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY)

Man Group plc lifted its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 375.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 177,962 shares of the medical instruments supplier's stock after acquiring an additional 140,503 shares during the period. Man Group plc owned 0.09% of DENTSPLY SIRONA worth $3,378,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Nomura Holdings Inc. acquired a new position in DENTSPLY SIRONA during the fourth quarter worth approximately $501,000. Mork Capital Management LLC acquired a new position in DENTSPLY SIRONA during the fourth quarter worth approximately $1,002,000. Moore Capital Management LP acquired a new position in DENTSPLY SIRONA during the fourth quarter worth approximately $2,248,000. Lazard Asset Management LLC increased its position in DENTSPLY SIRONA by 23.0% during the fourth quarter. Lazard Asset Management LLC now owns 8,044,228 shares of the medical instruments supplier's stock worth $152,678,000 after buying an additional 1,505,928 shares during the period. Finally, Invenomic Capital Management LP increased its position in DENTSPLY SIRONA by 201.0% during the fourth quarter. Invenomic Capital Management LP now owns 2,639,161 shares of the medical instruments supplier's stock worth $50,091,000 after buying an additional 1,762,428 shares during the period. Institutional investors and hedge funds own 95.70% of the company's stock.

DENTSPLY SIRONA Price Performance

Shares of DENTSPLY SIRONA stock traded up $0.87 during trading on Tuesday, reaching $16.34. The company's stock had a trading volume of 2,368,514 shares, compared to its average volume of 2,966,347. The company has a quick ratio of 0.84, a current ratio of 1.25 and a debt-to-equity ratio of 0.72. DENTSPLY SIRONA Inc. has a 12-month low of $12.16 and a 12-month high of $28.25. The company has a market capitalization of $3.26 billion, a P/E ratio of -7.89, a price-to-earnings-growth ratio of 1.80 and a beta of 0.92. The business has a 50 day moving average price of $14.48 and a 200-day moving average price of $17.06.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $0.43 earnings per share for the quarter, beating analysts' consensus estimates of $0.29 by $0.14. DENTSPLY SIRONA had a positive return on equity of 12.62% and a negative net margin of 10.59%. The firm had revenue of $879.00 million for the quarter, compared to the consensus estimate of $854.75 million. During the same period in the previous year, the business earned $0.42 earnings per share. The company's revenue for the quarter was down 7.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current year.

DENTSPLY SIRONA Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 11th. Investors of record on Friday, June 27th will be paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 3.92%. DENTSPLY SIRONA's dividend payout ratio (DPR) is presently -14.10%.

Insider Activity at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director Gregory T. Lucier purchased 15,142 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were purchased at an average cost of $16.51 per share, for a total transaction of $249,994.42. Following the completion of the purchase, the director now directly owns 81,971 shares in the company, valued at $1,353,341.21. This represents a 22.66% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.50% of the company's stock.

Analyst Ratings Changes

Several research analysts have commented on XRAY shares. UBS Group cut their price target on DENTSPLY SIRONA from $27.00 to $25.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Wells Fargo & Company cut their price target on DENTSPLY SIRONA from $20.00 to $19.00 and set an "equal weight" rating on the stock in a research report on Friday, February 28th. Wall Street Zen raised DENTSPLY SIRONA from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Piper Sandler dropped their target price on DENTSPLY SIRONA from $20.00 to $16.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. Finally, Morgan Stanley lowered DENTSPLY SIRONA from an "overweight" rating to an "equal weight" rating and set a $14.00 target price on the stock. in a report on Tuesday, April 15th. Eleven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $20.36.

DENTSPLY SIRONA Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.